Cargando…

A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses

BACKGROUND: Lung adenocarcinoma (LUAD) kills millions of people every year. Recently, FDA and researchers proved the significance of high tumor mutational burden (TMB) in treating solid tumors. But no scholar has constructed a TMB-derived computing framework to select sensitive immunotherapy/chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wenlong, Wei, Chuzhong, Huang, Fengyu, Huang, Wencheng, Xu, Xiaoxin, Zhu, Xiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349266/ https://www.ncbi.nlm.nih.gov/pubmed/37456238 http://dx.doi.org/10.3389/fonc.2023.1104137

Ejemplares similares

Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma
por: Wu, Gujie, et al.
Publicado: (2023)

Tumor Mutational Burden Associated With Response to Hyperthermic Intraperitoneal Chemotherapy
por: Zeng, Lisi, et al.
Publicado: (2022)

Establishing a Macrophage Phenotypic Switch-Associated Signature-Based Risk Model for Predicting the Prognoses of Lung Adenocarcinoma
por: Chen, Jun, et al.
Publicado: (2022)

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma
por: Xiang, Luochengling, et al.
Publicado: (2020)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
por: Wang, Peipei, et al.
Publicado: (2021)

Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses
por: Liu, Yu-Qing, et al.
Publicado: (2019)

Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma
por: Li, Lin, et al.
Publicado: (2023)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

Predicting Tumor Mutational Burden From Lung Adenocarcinoma Histopathological Images Using Deep Learning
por: Niu, Yi, et al.
Publicado: (2022)

Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients
por: Wang, Zhe, et al.
Publicado: (2021)

miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma
por: Xue, Weijie, et al.
Publicado: (2021)

Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma
por: Zhai, Xiaoqian, et al.
Publicado: (2021)

Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma
por: Jia, Mingming, et al.
Publicado: (2020)

Computational Image Analysis Identifies Histopathological Image Features Associated With Somatic Mutations and Patient Survival in Gastric Adenocarcinoma
por: Cheng, Jun, et al.
Publicado: (2021)

Complete Response to Immunotherapy Combined With Chemotherapy in a Patient With Gynecological Mixed Cancer Mainly Composed of Small Cell Neuroendocrine Carcinoma With High Tumor Mutational Burden: A Case Report
por: Su, Xingyun, et al.
Publicado: (2022)

DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy
por: Dardare, Julie, et al.
Publicado: (2022)

Clinical Features and Prognoses of IgG4-Positive and IgG4-Negative Lacrimal Lymphomas
por: Liu, Rui, et al.
Publicado: (2021)

Epidemiological characteristics, clinical presentations, and prognoses of pediatric brain tumors: Experiences of national center for children’s health
por: Yang, Wei, et al.
Publicado: (2023)

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
por: Kim, Jinchul, et al.
Publicado: (2020)

Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis
por: Wu, Rui-Yan, et al.
Publicado: (2023)

Small bowel adenocarcinomas with favorable prognoses by radical resection and adjuvant chemotherapy: a case series of five cases
por: Nishioka, Yuri, et al.
Publicado: (2023)

The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients
por: Wang, Jie, et al.
Publicado: (2021)

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
por: Duan, Xiao-Peng, et al.
Publicado: (2023)

Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation
por: Peng, Jianfeng, et al.
Publicado: (2021)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
por: Lin, Chen, et al.
Publicado: (2020)

piR-hsa-211106 Inhibits the Progression of Lung Adenocarcinoma Through Pyruvate Carboxylase and Enhances Chemotherapy Sensitivity
por: Liu, Yongmei, et al.
Publicado: (2021)

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer
por: Dai, Jiawei, et al.
Publicado: (2021)

Nomogram for Predicting the Prognoses of Patients With Pancreatic Head Cancer After Pancreaticoduodenectomy: A Population-Based Study on SEER Data
por: Zhang, Wei, et al.
Publicado: (2021)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
por: Guo, Zixin, et al.
Publicado: (2021)

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
por: Shibata, Hirofumi, et al.
Publicado: (2021)

Clinicopathological Features and Prognoses in Patients With Brain Metastases From Small-Cell Esophageal Carcinoma: A Retrospective Analysis of 18 Patients
por: Jiao, Wenpeng, et al.
Publicado: (2021)

Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma： A Retrospective Study
por: Xiao, Yi, et al.
Publicado: (2022)

Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations
por: Xiu, Weigang, et al.
Publicado: (2021)

The Prognoses of Young Women With Breast Cancer (≤35 years) With Different Surgical Options: A Propensity Score Matching Retrospective Cohort Study
por: Li, Pei, et al.
Publicado: (2022)

Relevance of STK11 Mutations Regarding Immune Cell Infiltration, Drug Sensitivity, and Cellular Processes in Lung Adenocarcinoma
por: Li, Zhenqing, et al.
Publicado: (2020)

Leveraging various extracellular matrix levels to assess prognosis and sensitivity to immunotherapy in patients with ovarian cancer
por: Huang, Youqun, et al.
Publicado: (2023)

Construction of T cell exhaustion model for predicting survival and immunotherapy effect of bladder cancer based on WGCNA
por: Xue, Yuwen, et al.
Publicado: (2023)

Focal amplifications are associated with chromothripsis events and diverse prognoses in gastric cardia adenocarcinoma
por: Zhao, Xue-Ke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hhfujeetuj82vmbc5iegrd7t4b